Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...
Third indication beckons for Amgen's Uplizna Amgen is preparing to file a third indication for Uplizna, as a twice-yearly therapy for generalised myasthenia gravis, following new phase 3 data. R&D ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback